Brief: Zevra Therapeutics Ended Q3 2023 With $83.4M In Cash, Cash Equivalents, And Investments, Supporting Cash Runway Forecast Into 2026

Zevra Therapeutics

07/11/2023 12:06

Nov 7 (Reuters) - Zevra Therapeutics Inc  ZVRA.O :
    * ENDED Q3 2023 WITH $83.4M IN CASH, CASH EQUIVALENTS, AND
INVESTMENTS, SUPPORTING OUR FORECASTED CASH RUNWAY INTO 2026
    * QTRLY LOSS PER SHARE $0.40
    * Q3 EARNINGS PER SHARE VIEW $-0.30 -- LSEG IBES DATA

Source text for Eikon:  ID:nGNX8KFKjM 
Further company coverage:  ZVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))